Khmelnitskiy, Ukraine Clinical Trials

A listing of Khmelnitskiy, Ukraine clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

antirheumatics
methotrexate
rheumatism
stiffness
Clinic of Scientific Research Institute of Invalid Rehabilitation /ID# 228955
 (64.8 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +292 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

measurable disease
advanced cancer
solid tumor
cancer of the ovary
cancer
Podillya Regional Center of Oncology ( Site 1708)
 (67.7 away) Contact site
  • 16 views
  • 01 Aug, 2021
  • +148 other locations
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

This is a Phase 2, open-label study to evaluate PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected adult subjects with metastatic NSCLC who are PD-1/PD-L1 inhibitor nave and have progressed on a platinum based chemotherapy regimen.

measurable disease
cancer chemotherapy
pd-1 inhibitor
lung carcinoma
Municipal Non-profit Enterprise "SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC"
 (108.0 away) Contact site
  • 0 views
  • 07 Jul, 2021
  • +69 other locations